Novo Nordisk registers Phase 3 zenagamtide trial in T2D and first-in-human study for NNC0705-0002
Two new trial registrations posted to ClinicalTrials.gov cover a Phase 3 diabetes trial and an early-stage cardiometabolic inflammation study.
Novo Nordisk's latest registry filings show one late-stage cardiometabolic trial and one first-in-human study.
- AMBITION 7 (NCT07797335) is a Phase 3 trial comparing zenagamtide against insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications.1 The study is recruiting, with enrollment estimated at 1778 participants,1 and the primary outcome is non-inferiority of zenagamtide versus insulin glargine measured as change in haemoglobin A1c from baseline to week 52.1
- NCT07797855 is a first-in-human study of NNC0705-0002, a new medicine being developed for conditions where inflammation may contribute to heart and metabolic health problems.2 The trial is not yet recruiting and will assess the safety, tolerability, pharmacokinetics, target engagement, and metabolism of NNC0705-0002 after single and multiple doses in healthy adults,2 with enrollment estimated at 112 participants.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.